Background: Baseline serum creatinine (SCr) level is frequently not measured in clinical practice.
Background
Acute kidney injury (AKI) is commonly associated with high morbidity and mortality in critically ill patients [1] [2] [3] [4] . Even a modest degree of AKI is associated with mortality, morbidity, and increased healthcare cost [5] [6] [7] [8] [9] [10] . The Kidney Disease: Improving Global Outcomes (KDIGO) criteria was developed and validated to standardize the diagnosis and severity of AKI based on absolute or relative increases from baseline serum creatinine (SCr) levels, as well as progressive oliguria [11] . Thus, determination of baseline SCr is important to diagnose and classify AKI [12, 13] .
Despite development of the KDIGO criteria, classification of AKI remains challenging, as baseline outpatient SCr measurement-a marker of kidney function prior to the critical illness-is often unavailable [14] . In this case, the Acute Dialysis Quality Initiative (ADQI) has recommended backward calculation of baseline SCr using the Modification of Diet in Renal Disease (MDRD) formula, this formula assumes an estimated glomerular filtration rate (eGFR) value of 75 ml/min/1.73 m 2 (SCr ) for all patients with missing data [15] . However, backward calculation can lead to misclassification of AKI, particularly in the early stages of this syndrome [16, 17] .
The European Renal Best Practice (ERBP) recently proposed using the first documented SCr value on hospital admission (SCr ADM )-rather than SCr GFR-75 -as the baseline SCr when baseline outpatient SCr measurements are missing [18] . However, the use of SCr ADM as the baseline SCr can be inaccurate in patients with communityacquired AKI, as the SCr may have already increased prior to hospitalization [19, 20] . Additionally, the predictive performance of these two methods on mortality has not been well studied [18] .
The primary objective of this study was to compare the incidence and staging of AKI according to SCr criteria using SCr versus SCr ADM . The secondary objective of this study was to determine the accuracy of AKI diagnosis in critically ill patients using SCr estimation, based on assumed GFR and SCr ADM , compared to the reference standard of SCr measurement.
Methods

Study Population
This is a single-center retrospective study conducted at a tertiary referral hospital. We studied all adult patients (age ≥18 years) admitted to the ICU at Mayo Clinic in Rochester, MN, from January 1, 2011 through December 31, 2011. We included patients who had at least one SCr measured during the ICU admission. Patients with a history of stage 5 chronic kidney disease (CKD) or end-stage renal disease (ESRD), patients who received any dialysis modalities within 14 days prior to the ICU admission, and those who did not provide research authorization were excluded from the study. Stage 5 CKD and ESRD were identified based on ICD-9 code assignment (Additional file 1: Table S1 ) or baseline outpatient SCr-calculated eGFR of <15 ml/min/1.73 m 2 . For patients with multiple ICU admissions, only the first ICU admission during the study period was included in the analysis. This study was approved by the Mayo Clinic institutional review board.
We divided eligible patients into two groups, based on the availability of outpatient SCr between 365 and 7 days prior to hospital admission (Fig. 1) . One group included patients without baseline outpatient SCr (n = 3504). This is the cohort of patients for whom the use of surrogates for baseline SCr was actually applied. This cohort was used to compare the incidence and outcomes of AKI using SCr GFR-75 versus SCr ADM in order to represent the real-world finding. The second group included patients with baseline outpatient SCr (n = 4268).
Simulated cohort
AKI diagnosis based on outpatient SCr baseline can be used as a reference standard to assess the sensitivity and specificity of AKI diagnosis using various surrogate estimates. However, due to significant differences in clinical characteristics between patients with and without outpatient SCr (Table 1) , the finding in the cohort of patients with outpatient SCr might not be generalizable to patients without outpatient SCr. Therefore, we developed a propensity score model in which the outcome was whether baseline SCr was missing (n = 3504) or not n = 4268) to predict the likelihood of missing baseline SCr. The propensity model included age, race, diabetes mellitus, hypertension, coronary artery disease, stroke, peripheral vascular disease, congestive heart failure, and APA-CHE III at ICU admission as covariates. We applied this model to the group of patients with baseline outpatient SCr and then selected patients with a propensity score of ≥0.354 (post-hoc cut-off) to generate a study cohort of patients with similar characteristics to patients whose baseline SCr was not available, while preserving known baseline SCr (n = 3566). We used this simulated cohort to analyze the sensitivity and specificity of AKI diagnosis based on different surrogates. AKI diagnosis based on outpatient SCr was used as the reference standard.
Data collection
Clinical characteristics, demographic information, and laboratory data were collected using manual and automated retrieval from the institutional electronic medical records. We utilized data from the Mayo Clinic Life Science System (MCLSS) and the Multidisciplinary Epidemiology and Translational Research in Intensive Care (METRIC) database. The MCLSS database contained demographic characteristics, clinical data, hospital admission information, diagnosis codes, procedure codes, laboratory test results, and flowsheet data of both in-and outpatients at our institution [21] . The METRIC database contained ICU admission information, pertinent vital signs, fluid input/output, and medication administration record data of all patients admitted in ICU at our institution [22] . Data variables collected included age, sex, race, known comorbidities at hospital admission, ICU type, severity of illness at ICU admission, ICU length of stay, and ICU discharge status. SCr measurements were collected for each eligible patient up to one year prior to ICU admission. The baseline outpatient SCr was defined as the most recent outpatient SCr measured between 365 and 7 days prior to the hospital admission. The eGFR was derived using the MDRD equation, with CKD being defined as a calculated eGFR of <60 ml/ min/1.73 m 2 . We identified comorbidities from clinical notes in electronic medical record using a validated electronic note search strategy [21] . The severity of illness at ICU admission was evaluated using the Acute Physiology and Chronic Health Evaluation (APACHE) III score [23] .
AKI diagnosis and classification
We identified and staged AKI based solely on the SCr criterion of the KDIGO definition [11] . AKI was defined 
Clinical outcomes
The primary outcome was all-cause mortality at 60 days following ICU admission. We reviewed patient vital statistics by reviewing the patient registration and electronic medical records. In patients whose vital status at 60 days after ICU admission was unknown, the Social Security Death Index was used [24] .
Statistical analysis
Continuous variables were reported as mean with standard deviation (SD) or median with interquartile range (IQR), as appropriate. All categorical variables were reported as counts with percentages. The difference in the AKI diagnosis using SCr ADM andSCr GFR-75 was assessed using McNemar's test. The agreement of AKI diagnosis and staging, based on SCr ADM and SCr GFR-75 , was assessed using Cohen's weighted kappa coefficient with linear weight between AKI stages. According to the results of AKI diagnosis, based on SCr ADM and SCr GFR-75 , we classified patients into 4 groups: (1) patients who had AKI regardless of baseline SCr calculation method, (2) patients who had AKI based only on SCr ADM , (3) patients who had AKI only based on SCr GFR-75 , and (4) patients who did not have AKI, regardless of baseline SCr determination methodology. We adjusted the odds ratio (OR) for age, ICU type, and APACHE III scores to assess 60-day mortality for the first three groups, using the fourth group as the reference group. The association between AKI stages and 60-day mortality was assessed using a logistic regression analysis. The predictive performance of the SCr criterion, using SCr ADM and SCr GFR-75 , for 60-day mortality was assessed by C-statistics, after which we compared their performances using Delong's test. We calculated net reclassification improvement to evaluate how using SCr GFR-75 as baseline renal function for AKI diagnosis changed risk classification for 60-day mortality. Sensitivities and specificities were compared using McNemar's test. To determine the optimal GFR used for SCr estimation, we estimated based on an assumed GFR with an increment of 5 ml/min/1.73 m 2 , ranging from 30 to 120 ml/min/1.73 m 2 . The sensitivity and specificity of AKI diagnosis, according to the estimated SCr of each assumed GFR, was calculated using AKI diagnosis according to the baseline outpatient SCr as a reference standard. The Youden index, which yielded the highest sum of sensitivity and specificity, was used to identify the optimal GFR used for SCr estimation. The subgroup analyses, based on sex, age, and the presence of abnormal renal function at presentation, were performed to investigate the optimal GFR used in each subgroup. A two-sided p value of less than 0.05 was considered statistically significant. All analyses were performed using JMP statistical software (version 10.0, SAS, Cary, NC).
Results
During the study period, 9277 critically ill patients were admitted to the ICU. Of these, 1,505 were excluded: 498 did not provide authorization to use their data for research, 194 aged < 18 years, and 386 had no measured SCr values in ICU, 427 had ESRD, or received dialysis within 14 days prior to ICU admission. Thus, 7772 patients were included in this study. The baseline outpatient SCr was not available for 3504 of these patients (45.1 %). The clinical characteristics of these patients upon ICU admission and their outcomes are summarized in Table 1 . Patients who had available baseline outpatient SCr were older, Caucasian, had more known comorbidities, and had higher APACHE and SOFA scores at ICU admission. Patients in the simulated cohort had similar characteristics to patients without baseline outpatient SCr.
AKI diagnosis and staging using the admission and estimated SCr
Among patients without baseline outpatient SCr, using SCr ADM , AKI occurred in 571 patients (16.3 %), with 12.1 % in stage 1, 2.3 % in stage 2, and 1.9 % in stage 3. UsingSCr GFR-75 , AKI occurred in 997 patients (28.4 %), with 15.6 % in stage 1, 7.4 % in stage 2 and 5.5 % in stage 3. SCr GFR-75 classified more patients into AKI than SCr ADM (p < .001) ( Table 2) .
The percentage agreement for AKI diagnosis using SCr ADM and SCr GFR-75 for baseline SCr estimation was 79.5 % with a kappa of 0.42 (95 % CI, 0.39-0.46). SCr ADM and SCr GFR-75 as baseline SCr agreed in 425 AKI cases and 2361 non-AKI cases. Using SCr ADM and SCr GFR-75 resulted in a discrepancy in AKI diagnoses of 718 cases (20.5 %). 146 patients met the AKI diagnosis by only SCr ADM and 572 met the AKI diagnosis using only SCr . The percentage agreement for AKI staging, using both SCr ADM and SCr GFR-75 , was 74.4 % with a kappa of 0.39 (95 % CI, 0.36-0.42). Ninety six percent of AKI based only by SCr GFR-75 but not SCr ADM occurred within 24 hours of ICU admission.
Risk for 60-day mortality
Of the total cohort, 8.5 % (N = 298) died within 60 days of ICU admission. The 60-day mortality rates after ICU admission for AKI stages by using SCr ADM and SCr are shown in Fig. 2 Fig. 3 ). Calculating the performance for prediction of 60-day mortality, the C-statistic for AKI stages using SCr ADM and SCr GFR-75 as baseline SCr were 0.64 and 0.68 respectively (p = .001). Using SCr for AKI diagnosis improved risk classification for 60-day mortality with net reclassification improvement of 4.7 %.
Sensitivity and specificity for AKI diagnosis
In the simulated cohort of patients with available baseline outpatient SCr, the mean baseline SCr (SD) was 1.1 ± 0.4 mg/dL. Of these patients, 20.7 % (n = 738) experienced AKI using known baseline outpatient SCr, 14.6 % (n = 520) using SCr ADM , and 25.7 % (n = 915) using SCr . Application of SCr GFR-75 as baseline SCr yielded a sensitivity of 77.2 % and specificity of 87.8 % for the AKI diagnosis. Using SCr ADM as baseline SCr yielded a sensitivity of 50.5 % and specificity of 94.8 %. Overall, SCr GFR-75 was more sensitive (p < .001) , whereas SCr ADM was found to be more specific (p < .001). The application of either SCr or SCr ADM , compared to AKI diagnosis and staging based on baseline outpatient SCr, resulted in bi-directional misclassification of AKI (Additional file 1: Table S2 ).
Optimal GFR used for SCr estimation
The sensitivity and specificity of AKI diagnosis, when using different assumed GFR for SCr estimation, were shown in Table 4 . The most optimal GFR with the highest sum of sensitivity and specificity was 85 ml/min/1.73 m 2 , yielding a sensitivity of 85.2 % and a specificity of 83.0 %. The sensitivity and specificity in different subgroups based on sex, age, and the presence of abnormal renal function at presentation are summarized in Additional file 1: Table  S3 with the most optimal GFR for SCr estimation indicated. The application of SCr ADM for AKI diagnosis in patients with abnormal renal function at presentation resulted in significantly lower sensitivity (41.7 vs. 65 %), but similar specificity (92.7 vs. 95.3 %), for AKI diagnosis.
Discussion
We conducted a retrospective cohort study to assess the effect of using different baseline SCr methods, SCr GFR-75 and SCr ADM , on the incidence of AKI as well as prognostication performance of the KDIGO definition. We demonstrated that using SCr GFR-75 as a baseline SCr for AKI diagnosis was associated with the larger number of classified AKI cases. However, using SCr GFR-75 resulted in the misclassification of non-AKI cases into AKI, as AKI cases only by SCr GFR-75 , but not SCr ADM , had a no significant increase in 60-day mortality risk. This finding is consistent with SCr GFR-75 as a more sensitive and SCr ADM as a more specific surrogate for AKI diagnosis when compared with outpatient SCr as the reference standard. Ideally, outpatient SCr values, which are reflective of patient pre-morbid kidney function, should be used as the baseline SCr for AKI diagnosis [25] . However, the lack of baseline outpatient SCr level is a common problem encountered in clinical practice [25, 26] . Following the ADQI statement, the use of SCr GFR-75 as a baseline SCr has been shown to lead to misclassification of AKI in ICU patients [16, 17] and following cardiac surgery [27] . The European Renal Best Practice (ERBP) has recommended the use of SCr ADM , rather than SCr GFR-75 , when baseline outpatient SCr measurements are not available [18] . In our study, we demonstrated that using either SCr or SCr ADM led to misclassification of AKI diagnosis and staging. Use of SCr has been shown to inflate AKI incidence, whereas use of SCr ADM underestimates AKI incidence [14, 16, 17] . The inflation of AKI diagnosis bySCr GFR-75 as surrogates for baseline kidney function was due to inaccurate baseline SCr estimation in patients with chronic kidney disease [14, 28] . In contrast, the underestimation of AKI diagnosis when using SCr ADM was due to the under-diagnosis of community-acquired AKI [14] . We found most of AKI cases missed by SCr ADM occurred within the first 24 hours of ICU admission.
The analysis in a simulated cohort of patients with baseline outpatient SCr showed the higher sensitivity and lower specificity of AKI diagnosis bySCr GFR-75 in comparison with SCr ADM. The decision to use SCr or SCr ADM for AKI diagnosis and classification depends on the purpose of the AKI definition. In clinical practice, AKI prevention and prompt treatment might improve patient outcomes. Thus, for risk stratification purposes in clinical practice, we encourage the use of SCr GFR-75 for AKI diagnosis, as it can conceivably identify more AKI cases. Conversely, for research studies that enroll patients with AKI for invasive tests or treatments, using SCr ADM may be more suited, as it would be more likely to enroll patients who are going to benefit from the intervention.
The use of estimated SCr by back-calculation with the MDRD formula can allow investigators or clinicians to be more flexible regarding the sensitivity and specificity of Fig. 3 Odds ratio for 60-day mortality in patients with or without acute kidney injury using admission SCr and GFR-estimated SCr as baseline the AKI definition. As shown in Table 4 and Additional file 1: Table S3 , when using different assumed GFR for SCr estimation, it provides different levels of sensitivity and specificity that we may individualize in each patient in different encounters. Since GFR decreases with age, the use of SCr GFR-75 might result in over-AKI classification in the elderly [29] , therefore use of a different assumed GFR for SCr estimation could be considered in different age groups. For example, using SCr GFR-70 in elderly but SCr GFR-100 in younger adult would yield the highest sum of sensitivity and specificity. In addition, abnormal renal function at presentation may be due to pre-existing chronic kidney disease or due to acute elevation of SCr from community-acquired acute kidney injury. Therefore, estimated SCr based on lower assumed GFR might be more suitable for patients without baseline outpatient SCr, who present initially with an abnormal SCr. In contrast, using SCr ADM in patients with abnormal renal function based on initial SCr value in hospital would result in lower sensitivity in the diagnosis of AKI. This study has several limitations.
(1) This is a singlecenter retrospective study. (2) We did not include the urine output criterion for AKI diagnosis since an indwelling urinary catheter was not used to obtain accurate hourly urine output data for all critically ill patients. (3) Our study compared only two common surrogates for baseline SCr and did not include other advanced methods to estimate the baseline SCr. For example, Siew and colleagues recently demonstrated that a multiple imputation method can improve accuracy in estimating missing baseline SCr and reduce misclassification of AKI [30] . However, the use of this technique in clinical practice is limited and still requires further validation. A multi-center prospective study is ultimately required to address some of these limitations.
Conclusion
When baseline outpatient SCr was not available, using SCr GFR-75 as a surrogate for baseline SCr was found to be more sensitive but less specific for AKI diagnosis compared to SCr ADM . This resulted in higher incidence of AKI with larger likelihood of false-positive cases.
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